Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 3, 2012, Pages 1427-1432

  Krenitsky, Véronique Plantevin ^a   Delgado, Mercedes ^a   Nadolny, Lisa ^a   Sahasrabudhe, Kiran ^a   Ayala, Leticia ^a   Clareen, Steven S ^a   Hilgraf, Robert ^a   Albers, Ronald ^a   Kois, Adam ^a   Hughes, Kevin ^a   Wright, Jonathan ^a   Nowakowski, Jacek ^a   Sudbeck, Elise ^a   Ghosh, Sutapa ^a   Bahmanyar, Sogole ^a   Chamberlain, Philip ^a   Muir, Jeff ^a   Cathers, Brian E ^a   Giegel, David ^a   Xu, Li ^a   Celeridad, Maria ^a   Moghaddam, Mehran ^a   Khatsenko, Oleg ^a   Omholt, Paul ^a   Katz, Jason ^a   Pai, Sema ^a   Fan, Rachel ^a   Tang, Yang ^a   Shirley, Michael A ^a   Benish, Brent ^a   Blease, Kate ^a   Raymon, Heather ^a   Bhagwat, Shripad ^a   Henderson, Ian ^b   Cole, Andrew G ^b   Bennett, Brydon ^a   Satoh, Yoshitaka ^a   more..

^a CELGENE CORPORATION   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Aminopurine; Ischemia reperfusion injury; Jun N terminal kinase inhibitor; Structure based drug design

Indexed keywords

2,4 DICHLORO 5 NITROPYRIMIDINE; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; PURINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STABILITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; ISCHEMIA; LIVER ISCHEMIA; MALE; MOUSE; NONHUMAN; RAT; REPERFUSION INJURY;

2-AMINOPURINE; ANIMALS; CATALYTIC DOMAIN; DOGS; ENZYME ACTIVATION; ENZYME INHIBITORS; HAPLORHINI; INHIBITORY CONCENTRATION 50; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PURINES; RATS; REPERFUSION INJURY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84856233549     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.12.028     Document Type: Article

References (45)

1. D.A. Liem, Honda, M. Henry, J. Zhang, D. Woo, and P. Ping J. Appl. Physiol. 103 2007 2129
2. P.K. Chatterjee Naunyn-Schmiedeberg's Arch. Pharmacol. 376 2007 1
3. M.A. Zaouali, H. Ben Abdennebi, S. Padrissa-Altes, A. Mahfoudh-Boussaid, and J. Rosello-Catafau Expert Opin. Pharmacother. 11 2010 537
4. M.A. Bogoyevitch, K.R.W. Ngoei, T.T. Zhao, Y.Y.C. Yeap, and D.C.H. Ng Biochim. Biophys. Acta, Proteins and Proteomics 1804 2010 463
5. M.A. Siddiqui, and P.A. Reddy J. Med. Chem. 53 2010 3005
6. T. Rückle, M. Biamonte, T. Grippi-Vallotton, S. Arkinstall, Y. Cambet, C. Chabert, D.J. Church, S. Halazy, X. Jiang, I. Martinou, A. Nichols, W. Sauer, and J.-P. Gotteland J. Med. Chem. 47 2004 6921
7. P. Gaillard, Jean-Claude, I. Etter, V. Ardissone, S. Arkinstall, Y. Cambet, M. Camps, C. Chabert, D. Church, R. Cirillo, D. Gretener, S. Halazy, A. Nichols, C. Szyndralewiez, P.-A. Vitte, and J.-P. Gotteland J. Med. Chem. 48 2005 4596
8. Y. Asano, S. Kitamura, T. Ohra, F. Itoh, M. Kajino, T. Tamura, M. Kaneko, S. Ikeda, H. Igata, T. Kawamoto, S. Sogabe, S.-I. Matsumoto, T. Tanaka, M. Yamaguchi, H. Kimurab, and S. Fukumotoa Bioorg. Med. Chem. 16 2008 4699
9. H. Cho, S.C. Black, D. Looper, M. Shi, D. Kelly-Sullivan, S. Timofeevski, K. Siegel, X.-H. Yu, S.R. McDonnell, P. Chen, J. Yie, K.M. Ogilvie, J. Fraser, and C.P. Briscoe Am. J. Physiol. 295 2008 1142
10. H. Zhao, M.D. Serby, Z. Xin, B.G. Szczepankiewicz, M. Liu, C. Kosogof, B. Liu, L.T.J. Nelson, E.F. Johnson, S. Wang, T. Pederson, R.J. Gum, J.E. Clampit, D.L. Haasch, C. Abad-Zapatero, E.H. Fry, C. Rondinone, J.M. Trevillyan, H.L. Sham, and G. Liu J. Med. Chem. 49 2006 4455
11. Uehara, T., Peng, Xing X., Bennett, B., Satoh, Y., Friedman, G., Currin, R., Brenner, D. A., Lemasters, J. Transplantation, 78, 324.
12. T. Uehara, B. Bennett, S.T. Sakata, Y. Satoh, G.K. Bilter, J.K. Westwick, and D.A. Brenner J. Hepatol. 42 2005 850
13. J. Kanellis, F.Y. Ma, R. Kandane-Rathnayake, J.P. Dowling, K.R. Polkinghorne, B.L. Bennett, G.C. Friedman, and D.J. Nikolic-Paterson Nephrol. Dial. Transplant. 25 2010 2898
14. R.S. Flanc, F.Y. Ma, G.H. Tesch, Y. Han, R.C. Atkins, B.L. Bennett, G.C. Friedman, J.-H. Fan, and D.J. Nikolic-Paterson Kidney Int. 72 2007 698
15. A. Tabata, M. Morikawa, M. Miyajima, B.L. Bennett, Y. Satoh, J. Huang, Yasuaki Tamura, N. Sato, and T. Abe Transplantation 83 2007 1358
16. X. Chen, J. Wu, D. Hua, K. Shu, J.-Z. Wang, L. Li, and T. Lei Brain Res. 1357 2010 104
17. Y. Wang, H.-X. Ji, S.-H. Xing, D.-S. Pei, and Q.-H. Guan Life Sci. 80 2007 2067
18. Q.-H. Guan, D.-S. Pei, Q.-G. Zhang, Z.-B. Hao, T.-L. Xu, and G.-Y. Zhang Brain Res. 1035 2005 51
19. M. Ishii, Y. Suzuki, K. Takeshita, N. Miyao, H. Kudo, R. Hiraoka, K. Nishio, N. Sato, K. Naoki, T. Aoki, and K. Yamaguchi J. Immunol. 172 2004 2569
20. Compound 1 was obtained as a result of a high throughput screen and subsequent hit-to-lead optimization through a collaboration with Pharmacopeia Drug Discovery Inc.
21. See Supplementary data for experimental details on JNK1, JNK2, JNK3, and p38α enzymatic assays.
22. M.R. Lee, and C. Dominquez Curr. Med. Chem. 12 2005 2979
23. C. Dominquez, D.A. Powers, and N. Tamayo Curr. Opin. Drug Discov. Dev. 8 2005 421
24. D.M. Goldstein, and T. Gabriel Curr. Top. Med. Chem. 5 2005 1017
25. Sabat, M., Clark, M. P., Brugel, T. A., Golebiowski, A., Van Rens, J. C., De, B. U.S. 2007, 20 pp US 7256196 B1 20070814.
26. A.G. Cole, A. Metzger, G. Ahmed, M.-R. Brescia, R.J. Chan, J. Wen, L. O'Brien, L.-Y. Qin, and I. Henderson Tetrahedron Lett. 47 2006 8897
27. Albers, R. J., Ayala, L., Clareen, S. S., Delgado Mederos, M. M., Hilgraf, R., Hegde, S. G., Hughes, K., Kois, A., Plantevin-Krenitsky, V., McCarrick, M., Nadolny, L., Palanki, M. S. S., Sahasrabudhe, K., Sapienza, J., Satoh, Y., Sloss, M. K., Sudbeck, E., Wright, J., Henderson, I., Cole, A.G. (Signal Pharmaceuticals, LLC, USA) U.S. Patent No. 7,723,340 (Issued 5/25/2010).
28. Davis-Ward, R., Mook, Jr., R. A., Neeb, M. J; Salovich, J. M. PCT Int. Appl. 2004, 115 pp WO 2004074244 A2 20040902.
29. The JNK3 isoform was the only one available to us for crystallography during this drug discovery program. All residues invoked in the following discussion refer to the JNK3 isoform. X. Xie, Y. Gu, T. Fox, J.T. Coll, M.A. Fleming, W. Markland, P.R. Caron, K.P. Wilson, and M.S. Su Structure 6 1998 983 The PDB deposition codes for 1 in JNK3 complex crystal structure is 3TTJ
30. We observed this induced fit for the first time upon resolution of the crystal structure of 1 in the active site of JNK3. This phenomenon has since then been observed and reported by others. B.-M. Swahn, F. Huerta, E. Kallin, J. Malmstrom, T. Wegelt, J. Viklund, P. Womack, Y. Xue, and L. Ohberg Bioorg. Med. Chem. Lett. 15 2005 5095
31. B.-M. Swahn, Y. Xu, E. Arzel, E. Kallin, A. Magnus, N. Plobeck, and J. Viklund Bioorg. Med. Chem. Lett. 16 2006 1397
32. T. Tamenecka, R. Jiang, X. Song, D. Duckett, W. Chen, Y.Y. Ling, J. Habel, J.D. Laughlin, J. Chambers, M. Figuera-Losada, M.D. Cameron, L. Lin, C.H. Ruiz, and P.V. LoGrasso J. Med. Chem. 53 2010 419
33. All images in this Letter were generated using The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC.
34. The metabolic stability of compounds 1 and 4-7 was evaluated based on the percentage of compound remaining after incubation for 60 min in rat and human S9 fractions. Compounds 4-7 were stable (>70% in both species). On the other hand, compound 1 was unstable in rat S9 fractions (35%) but stable in human S9 fractions (86%). N.H.P. Cnubben, J. Vervoort, M.G. Boersma, and Y.M.C.M. Rietjens Biochem. Pharmacol. 49 1995 1235
35. S.D. Nelson Curr. Ther. Res. 62 2001 885
36. A.S. Kalgutkar, I. Gardner, R.S. Obach, C.L. Shaffer, E. Callegari, K.R. Henne, A.E. Mutlib, D.K. Dalvie, J.S. Lee, Y. Nakai, J.P. O'Donnell, J. Boer, and S.P. Harriman Curr. Drug Met. 6 2005 161
37. This class of compounds is 8-10 times more potent in JNK2 and JNK3 than JNK1.
38. Although a JNK/p38α dual inhibitor profile was acceptable for the targeted indications, the impact of structural changes on p38α potency was monitored in this program and is reported in the discussion.
39. A diverse set of 20 aminopurine analogs including C2 anilines and C2 alkyl amines was tested in a panel of 75 kinases at a concentration of 10 μM. Clustering of the results revealed a clear trend between structure and selectivity where the highest GINI scores (>0.575) was observed for C2-alkyl amines and as low as 0.335 for C2 anilino substituents. Graczyk, P. P. J. Med. Chem. 2007, 50, 5773.
40. M. Ishikawa, and Y. Hashimoto J. Med. Chem. 54 2011 1539
41. F. Lovering, J. Bikker, and C. Humbler J. Med. Chem. 52 2009 6752
42. Our objective was to reach a solubility of 5 mg/mL at pH 5-8.
43. This assay measures c-Jun phosphorylating activity in cell lysates prepared from treated Jurkat T cells. See Supplementary data for experimental details.
44. See Supplementary data for experimental details on in vivo pharmacology models.
45. The metabolic stability of 2 was measured based on the percentage of compound remaining after incubation at a 3 μM concentration for 30 min in liver microsomes. While a minor loss in rat liver microsomes was observed (92% remaining), no metabolism was observed in mouse, dog, monkey, and human (100% remaining).